Business
Sunshine Biopharma Discusses the Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - February 17, 2021) - The Stock Day Podcast welcomed Sunshine Biopharma (OTC Pink: SBFM) ("the Company"), a company engaged
About this update from Sunshine Biopharma Inc.
[{"type":"text","content":"Phoenix, Arizona--(Newsfile Corp. - February 17, 2021) - The Stock Day Podcast welcomed Sunshine Biopharma (OTC Pink: SBFM) (\"the Company\"), a company engaged in the development of Adva-27a, a unique anticancer compound, as well as the development of a treatment for COVID-19. CEO of the Company, Dr. Steve Slilaty, joined Stock Day host, Everett Jolly.\nJolly began the interview by commenting on the Company's significant increase in stock price over the past several months. \"I think the market recognizes the significant progress that we've been making, and we're very excited about the science we've been doing,\" shared Dr. Slilaty.\n\"Could you give us an update on the licensing agreement with the University of Georgia?\", asked Jolly. \"Initially, we teamed up with the University of Georgia because they had worldwide renowned expertise in coronavirus protease inhibitors, and this is what our coronavirus treatment is centered around,\" explained Dr. Slilaty. \"The University of Georgia had two technologies which were already patented by them and we agreed that they would license them to us on an exclusive basis. In return, we would offer co-development of their compounds in parallel with our own.\"\nJolly then asked about the progress of the Company's COVID-19 treatment. \"We are now at the stage where we have initiated mice studies on our SBFM-PL4 protease inhibitor,\" said Dr. Slilaty, adding that the Company will also be including the licensed compounds from the University of Georgia in these studies. Dr. Slilaty then elaborated on the process of the mice studies, as well as what would occur in the event of a successful study. \"If that were the case, we would file our results with the FDA and request that the FDA authorizes us to proceed to test our compound on actual COVID-19 patients.\"\nThe conversation then turned to the Company's development of Adva-27a. \"So, that is our flagship anticancer compound,\" explained Dr. Slilaty. \"It is the only drug we're aware of anywhere in the world that works on multidrug resistant cancer cells,\" he shared. \"We're really excited about this. We have ordered a new batch of Adva-27a, and we're expecting delivery of the new batch any time now,\" said Dr. Slilaty, adding that the Company intends to use the compound in mice studies.\n\"What's next for the COVID-19 research plan?\", aske...